Login to Your Account

Financings NEWS
Tuned up for checkpoint combos

With $62 million in series B cash, Pionyr Immunotherapeutics Inc. hopes to "get initial human readouts in a couple of programs – at least one, maybe a second," CEO Steven James told BioWorld. The San Francisco-based company is advancing its Myeloid Tuning technology, which rebalances the tumor microenvironment, an effort that could work especially well with checkpoint inhibitors.

Allakos Inc., which has deflected questions about its technology since its 2012 founding, continued to let its fundraising prowess do the talking after completing a $100 million series B to advance AK-002, a therapeutic antibody the company called its lead program, in disease areas ranging from gastrointestinal (GI) to dermatologic and ocular diseases.

LONDON – Newco Northsea Therapeutics BV has sailed onto the scene with a portfolio of structurally engineered fatty acids and a €25 million series A funding round to take the lead product, icosabutate (PRC-4016), through phase IIb in the treatment of NASH.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: